MiRNA-based model for predicting the TMB level in colon adenocarcinoma based on a LASSO logistic regression method
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MiRNA-based model for predicting the TMB level in colon adenocarcinoma based on a LASSO logistic regression method
Authors
Keywords
-
Journal
MEDICINE
Volume 100, Issue 21, Pages e26068
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2021-05-25
DOI
10.1097/md.0000000000026068
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification and validation of a miRNA-related expression signature for tumor mutational burden in colorectal cancer
- (2021) Lijun Xu et al. World Journal of Surgical Oncology
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- miRNA-Based Feature Classifier Is Associated with Tumor Mutational Burden in Head and Neck Squamous Cell Carcinoma
- (2020) Yu Xia et al. Biomed Research International
- MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinoma
- (2019) Yufeng Lv et al. OncoImmunology
- Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells
- (2019) Peng-Fei Zhang et al. Molecular Cancer
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States
- (2018) Sumanta Kumar Pal et al. EUROPEAN UROLOGY
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive biomarkers for immune checkpoint inhibitor therapy: we need to keep searching
- (2018) Mary M. Huerter et al. Journal of Thoracic Disease
- Key questions about the checkpoint blockade-are microRNAs an answer?
- (2018) Dragomir Mihnea et al. Cancer Biology & Medicine
- Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients
- (2018) Dengbo Ji et al. EBioMedicine
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- New Dancing Couple: PD-L1 and MicroRNA
- (2017) A. Grenda et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
- (2016) K. A. Olaussen et al. ANNALS OF ONCOLOGY
- PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
- (2016) Aaron Goodman et al. Nature Reviews Clinical Oncology
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
- (2016) Dickran Kazandjian et al. ONCOLOGIST
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- PD-L1 Expression and Survival among Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy
- (2016) Steffen Filskov Sorensen et al. Translational Oncology
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
- (2016) Lian Zhao et al. Oncotarget
- Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
- (2016) Marios Giannakis et al. Cell Reports
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- Tumor neoantigens: building a framework for personalized cancer immunotherapy
- (2015) Matthew M. Gubin et al. JOURNAL OF CLINICAL INVESTIGATION
- The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
- (2015) Yu Fujita et al. MOLECULAR THERAPY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice
- (2015) Luís Felipe Campesato et al. Oncotarget
- Regularization Paths for Generalized Linear Models via Coordinate Descent
- (2015) Jerome Friedman et al. Journal of Statistical Software
- MicroRNAome genome: A treasure for cancer diagnosis and therapy
- (2014) Ioana Berindan-Neagoe et al. CA-A CANCER JOURNAL FOR CLINICIANS
- DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions
- (2014) Ioannis S. Vlachos et al. NUCLEIC ACIDS RESEARCH
- MicroRNAs in cancer: biomarkers, functions and therapy
- (2014) Josie Hayes et al. TRENDS IN MOLECULAR MEDICINE
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
- (2014) Limo Chen et al. Nature Communications
- Targeting PD-1/PD-L1 interactions for cancer immunotherapy
- (2012) Laurence Zitvogel et al. OncoImmunology
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started